Camber Pharmaceuticals is pleased to announce the addition of Sapropterin Dihydrochloride Tablets and Powder for Oral Solution to its current portfolio.
Sapropterin Dihydrochloride Tablets and Powder for Oral Solution are indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age or older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU).
Sapropterin Dihydrochloride Tablets are available in 100 mg strength,120 count bottles.
Sapropterin Dihydrochloride Powder for Oral Solution is available in 100 mg and 500 mg strengths that contain 30 single use packets per carton.
To find out more about Sapropterin Dihydrochloride Tablets please visit www.camberpharma.com/SapropterinTablets
To find out more about Sapropterin Dihydrochloride Powder for Oral Solution please visit www.camberpharma.com/SapropterinOralSol
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
SOURCE: Camber Pharmaceuticals